Recital 2, Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…

In forcesince 29 Mar 2006cited 1×

In the case of certain categories of medicinal products, however, in order to meet unmet medical needs of patients and in the interests of public health, it may be necessary to grant marketing authorisations on the basis of less complete data than is normally the case and subject to specific obligations, hereinafter ‘conditional marketing authorisations’. The categories concerned should be medicinal products which aim at the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases, or medicinal products to be used in emergency situations in response to public health threats recognised either by the World Health Organisation or by the Community in the framework of Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the epidemiological surveillance and control of communicable diseases in the Community [OJ L 268, 3.10.1998, p. 1. Decision as last amended by Regulation (EC) No 1882/2003 (OJ L 284, 31.10.2003, p. 1).], or medicinal products designated as orphan medicinal products in accordance with Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [OJ L 18, 22.1.2000, p. 1.].

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    Ainsi qu’il ressort des considérants 1 à 3 du règlement n o 507/2006 : « Avant d’obtenir l’[AMM] dans un ou plusieurs États membres, un médicament à usage humain doit généralement faire l’objet d’études approfondies …

    2 Mar 2022 · 62020TJ0556